| Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 … B Ricciuti, X Wang, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ... JAMA oncology 8 (8), 1160-1168, 2022 | 143 | 2022 |
| SMARCA4 and other SWItch/sucrose nonfermentable family genomic alterations in NSCLC: clinicopathologic characteristics and outcomes to immune checkpoint inhibition JV Alessi, B Ricciuti, LF Spurr, H Gupta, YY Li, C Glass, M Nishino, ... Journal of Thoracic Oncology 16 (7), 1176-1187, 2021 | 66 | 2021 |
| FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma JM Cleary, S Raghavan, Q Wu, YY Li, LF Spurr, HV Gupta, DA Rubinson, ... Cancer discovery 11 (10), 2488-2505, 2021 | 51 | 2021 |
| Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer G Montagna, HV Gupta, M Hannum, KS Tan, J Lee, JR Scarpa, G Plitas, ... British Journal of Anaesthesia 126 (2), 367-376, 2021 | 51 | 2021 |
| Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer B Ricciuti, JV Alessi, A Elkrief, X Wang, A Cortellini, YY Li, VR Vaz, ... Annals of Oncology 33 (10), 1029-1040, 2022 | 39 | 2022 |
| Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma JG Connolly, KS Tan, B Mastrogiacomo, J Dycoco, R Caso, GD Jones, ... British Journal of Anaesthesia 127 (1), 75-84, 2021 | 33 | 2021 |
| Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer AJ Church, LB Corson, PC Kao, A Imamovic-Tuco, D Reidy, D Doan, ... Nature medicine 28 (8), 1581-1589, 2022 | 20 | 2022 |
| Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study JB Yuval, J Lee, F Wu, HM Thompson, FS Verheij, HV Gupta, T Irie, ... British Journal of Anaesthesia 129 (2), 172-181, 2022 | 12 | 2022 |
| Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer H Singh, RB Keller, KS Kapner, J Dilly, S Raghavan, C Yuan, EF Cohen, ... Clinical Cancer Research 29 (22), 4627-4643, 2023 | 9 | 2023 |
| Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer P Tarantino, H Gupta, ME Hughes, J Files, S Strauss, G Kirkner, ... nature communications 14 (1), 7496, 2023 | 5 | 2023 |
| Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC JV Alessi, X Wang, A Elkrief, B Ricciuti, YY Li, H Gupta, LF Spurr, H Rizvi, ... Journal of Thoracic Oncology 18 (11), 1524-1537, 2023 | 5 | 2023 |
| Rare FGFR oncogenic alterations in sequenced pediatric solid and brain tumors suggest FGFR is a relevant molecular target in childhood cancer L Lazo De La Vega, H Comeau, S Sallan, A Al-Ibraheemi, H Gupta, YY Li, ... JCO Precision Oncology 6, e2200390, 2022 | 5 | 2022 |
| Rare FGFR oncogenic alterations in sequenced pediatric solid and brain tumors suggest FGFR is a relevant molecular target in childhood cancer LL De La Vega, H Comeau, S Sallan, A Al-Ibraheemi, H Gupta, YY Li, ... JCO Precision Oncology 6, 2022 | 5 | 2022 |
| Intraoperative ketorolac may interact with patient-specific tumour genomics to modify recurrence risk in lung adenocarcinoma: an exploratory analysis JG Connolly, JR Scarpa, HV Gupta, KS Tan, B Mastrogiacomo, J Dycoco, ... British Journal of Anaesthesia 127 (3), e82-e85, 2021 | 5 | 2021 |
| Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer B Ricciuti, A Elkrief, J Alessi, X Wang, Y Li, H Gupta, DM Muldoon, ... Clinical Cancer Research 29 (13), 2540-2550, 2023 | 4 | 2023 |
| SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: clinicopathological characteristics and outcomes to immune checkpoint inhibition J Alessi, B Ricciuti, L Spurr, H Gupta, YY Li, C Glass, M Nishino, ... J Thor Oncol 16, 1176-1187, 2021 | 3 | 2021 |
| Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer B Ricciuti, G Lamberti, SR Puchala, NR Mahadevan, JR Lin, JV Alessi, ... Journal of Clinical Oncology, JCO. 23.00580, 2024 | 2 | 2024 |
| Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer P Tarantino, HV Gupta, ME Hughes, JL Files, S Strauss, G Kirkner, ... Cancer Research 83 (5_Supplement), HER2-05-HER2-05, 2023 | 2 | 2023 |
| DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade. B Ricciuti, JVM Alessi, YY Li, MN Lawrence, H Gupta, M Nishino, ... Journal of Clinical Oncology 39 (15_suppl), 9113-9113, 2021 | 2 | 2021 |
| Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors A Groves, A Ward, YY Li, L Lazo de la Vega, A Nag, SJ Forrest, HV Gupta, ... Pediatric blood & cancer 70 (11), e30643, 2023 | 1 | 2023 |
Andrew CherniackBroad InstituteVerified email at broadinstitute.org
